Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 1
1989 3
1990 9
1991 5
1992 7
1993 9
1994 11
1995 11
1996 13
1997 7
1998 11
1999 7
2000 9
2001 8
2002 7
2003 8
2004 13
2005 13
2006 11
2007 5
2008 7
2009 11
2010 6
2011 6
2012 13
2013 14
2014 11
2015 14
2016 20
2017 21
2018 19
2019 18
2020 29
2021 42
2022 44
2023 29
2024 18
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Correspondence.
Achiron RN, Achiron A, Tuuminen R. Achiron RN, et al. Among authors: achiron a. Retina. 2021 Sep 1;41(9):e55-e56. doi: 10.1097/IAE.0000000000003184. Retina. 2021. PMID: 33840787 No abstract available.
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S; MAGNIFY-MS Study Group. de Stefano N, et al. Among authors: achiron a. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(4):e1187. doi: 10.1212/NXI.0000000000001187. Print 2022 Jul. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35701185 Free PMC article.
Uveitis-Glaucoma-hyphema Syndrome.
Gur Z, Tsumei E, Achiron A. Gur Z, et al. Among authors: achiron a. Nepal J Ophthalmol. 2016 Jan;8(15):99. doi: 10.3126/nepjoph.v8i1.16165. Nepal J Ophthalmol. 2016. PMID: 28242896
Use of corneal cross-linking beyond keratoconus: a systemic literature review.
Manns RPC, Achiron A, Knyazer B, Elhaddad O, Darcy K, Yahalomi T, Tole D, Avadhanam VS. Manns RPC, et al. Among authors: achiron a. Graefes Arch Clin Exp Ophthalmol. 2023 Sep;261(9):2435-2453. doi: 10.1007/s00417-023-05994-6. Epub 2023 Mar 7. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36881260
435 results